SecBot SecBot
8-K ·Filed Apr 13, 2026

SYRE

Spyre Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago SEC0001628280-26-024831
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The strong Phase 2 data for SPY001 in ulcerative colitis suggests a high probability of success in later-stage trials. Investors should monitor upcoming data readouts for SPY002 and SPY003 in mid-2026 and Q3 2026, respectively. The company's stock may experience positive momentum in the near term.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$63.27
T+0 close · Apr 13, 2026 · via day close
Latest settled
+50.78%
T+60 · $95.40
Vs SPY
+41.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $63.27entry
  2. T+1 · 7mo ago +1.17%α −0.04% · $64.01
  3. T+5 · 7mo ago +15.99%α +12.70% · $73.39
  4. T+20 · 6mo ago +20.80%α +13.07% · $76.43
  5. T+60 · 4mo ago +50.78%α +41.86% · $95.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics announced positive Phase 2 topline data for SPY001 in ulcerative colitis, showing statistically significant efficacy and a favorable safety profile. The company also announced the closure of Part A enrollment and the opening of Part B for additional cohorts, indicating continued clinical progress.

Key Facts

  • SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points in the Robarts Histopathology Index (RHI) score (p<0.0001)
  • Key secondary endpoints included a 40% clinical remission rate and 51% endoscopic improvement rate
  • SPY001 was well tolerated with a safety profile consistent with the 47 class, with no drug-related serious adverse events
  • Recruitment for Part A of the SKYLINE trial is closed, and enrollment is now open for Part B

Financial Impact

The positive topline data significantly improves the drug's development prospects, potentially increasing its market value by hundreds of millions of dollars

clinical trial progressiondrug development timelinemarket valuation

Risk Factors

  • Potential delays in regulatory approval
  • Competition from other ulcerative colitis treatments
  • Safety concerns in later-stage trials

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-024831
Exhibit: exhibit991-8xkdatarelease.htm0001628280-26-024831
Document: 0001628280-26-024831-index-headers.html0001628280-26-024831
Document: 0001628280-26-024831-index.html0001628280-26-024831
Document: 0001628280-26-024831.txt0001628280-26-024831

Track record

36 reports on SYRE

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 7h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026